Hints and tips:
...As we continued to Cape Evans, a conspiracy of wind and ice gathered behind us....
...“Many of the medicines selected for price setting already have significant rebates and discounts due to the robust private market negotiation that [already] occurs,” said Stephen J Ubl, Phrma chief executive...
...Chris Rossbach, a fund manager at J Stern & Co, said it had voted in favour of Disney’s board recommendations....
...Still, US bankruptcy Judge Michael Kaplan said the court remained “sceptical” about J&J’s prospects of finalising an agreement, as it makes a second attempt to resolve the lawsuits through a controversial...
...J&J reported earnings of $2.80, which were significantly above analyst expectations....
...Evan Seigerman, analyst at BMO Capital Markets, said drugs developed by Bristol, Pfizer, Lilly, Merck, AbbVie, and Amgen were likely to be on the initial CMS list....
...Janssen is the pharmaceutical division of J&J....
...J&J had created a $2bn fund to compensate victims under its previous legal strategy....
...It follows the US Court for Appeals ruling in January that shot down J&J’s attempt to implement a complex bankruptcy scheme called the “Texas-two step” to manage the claims....
...J&J said it stood behind the safety of its talcum powder and would immediately move for a stay of the Third Circuit Court’s opinion and also seek a review from the US Supreme Court....
...“The odds that we wake up and see a J&J or Lilly do something big like buying Alnylam, Incyte or Vertex goes down from where it would have been,” said Stifel’s Opler....
...JPMorgan Chase chief Jamie Dimon had a one-on-one lunch with US vice-president Kamala Harris at the White House last week, according to people familiar with the matter....
...MEG Energy appointed Darlene Gates as president and chief executive of the Canadian oil sands company, succeeding Derek Evans....
...Merck, BMS, J&J, Novartis and some trade groups have launched a legal broadside against them, filing lawsuits in several different courts across the US....
...J&J could not be immediately reached for comment on the Kenvue offering....
...Evan Seigerman, analyst at BMO Capital Markets, said the health benefits demonstrated by Novo’s trial now made it “unethical” for payers to not provide these potentially life-saving medications to patients...
...Evan Seigerman, an analyst at BMO Capital Markets, said Ricks has followed a strategy of “underpromising and overdelivering” as chief executive and avoiding some of the pitfalls that have affected rivals...
...Here’s the FT’s US pharmaceuticals correspondent Jamie Smyth. Jamie SmythA woman named Jacqueline Fox files a personal injury lawsuit against J&J....
...In March a judge dismissed J&J’s first attempt to use the bankruptcy courts to manage claims that its talcum powder could cause cancer....
...J&J’s consumer business, which is due to be spun off this year and renamed Kenvue, reported worldwide adjusted operational sales grew 3.9 per cent....
...The Third US Circuit Court of Appeals on Monday said it had dismissed the bankruptcy filing of J&J’s division LTL management, preventing the company from shifting thousands of legal claims out of trial courts...
...Under this strategy J&J had created a $2bn fund to compensate victims....
...J&J shares fell 2.8 per cent on Tuesday....
...J&J denies the claims but has offered plaintiffs an $8.9bn settlement, which would be paid over 25 years....
...claims target J&J’s new consumer carve-out On Twitter, follow Jamie Smyth (@JamieSmythF) and Michela Tindera (@mtindera07) Read a transcript of this episode on FT.com...
International Edition